The ability of the HIV virus to establish resistance to therapeutic drugs through genetic mutation is a major concern in the treatment of HIV/AIDS. With the increasing number of drug-resistant patients, it is of great importance in the development of new HIV/AIDS therapeutics that they will be effective against known resistance characteristics of HIV.
“RPI-MN has already been proven to have broad antiviral activity and a well established safety record in humans,” commented Dr Paul Reid, ReceptoPharm’s CEO.
“Recent laboratory studies revealed that RPI-MN was capable of inhibiting the replication of HIV as efficiently as normal or wild-type strains. This current study showing efficacy against resistant strains of the virus may allow us to quickly move into human clinical trials,” he concluded.